MK-1697

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameMK-1697
Drug Alias NameMK-1697
ClassificationBiologics
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsHead and Neck NeoplasmsColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaHong Kong
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsColorectal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A